<p>aTyr Pharma Inc.’s management held an investor call on September 15, 2025, where they announced that the EFZO-FIT study did not meet its primary endpoint regarding the change from baseline in mean daily OSC dose at week 48. During the call, management revealed the company’s next step is to engage with the FDA to determine a path forward following the disappointing topline results. The announcement led to a significant decline in aTyr’s stock price, dropping from $6.03 to $1.02 per share in a single day. The full interview can be accessed at here Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. aTyr Pharma Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1113706) on December 02, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)</p>

ATYR

<p>aTyr Pharma announced that the EFZO-FIT study missed its primary endpoint, leading to a significant stock price drop from $6.03 to $1.02. The company plans to engage with the FDA to determine next steps.</p>

aTyr Pharma Reveals EFZO-FIT Study Missed Primary Endpoint in Investor Call